Description

This fixed-dose combination tablet pairs efavirenz (a non-nucleoside reverse transcriptase inhibitor) with lamivudine and tenofovir disoproxil fumarate (nucleoside/nucleotide reverse transcriptase inhibitors). Commonly used in clinical first-line regimens (EFV 400–600?mg, 3TC 300?mg, TDF 300?mg), in research it enables modeling HIV-1 replication inhibition, study of resistance development, pharmacokinetics, PrEP protocols, and antiviral synergy . Each tablet delivers controlled dosing consistent with established clinical formulations. Strictly for research use only.

Product Specifications

Mechanism of Action & Research Applications

The combination works via dual mechanisms: efavirenz non?competitively inhibits HIV reverse transcriptase, while lamivudine and tenofovir act as chain?terminating analogs to block viral DNA synthesis. Research use includes modeling HIV replication inhibition, studying PrEP and antiviral resistance, exploring fixed-dose regimens’ pharmacodynamics, and evaluating drug interactions in vitro and in vivo settings.

Side Effects (For Reference Only in Research Models)

In research simulations or clinical analogs, typical observations may include neuropsychiatric effects (lightheadedness, vivid dreams, insomnia), headache, gastrointestinal discomfort, lipid elevation, renal stress, bone density changes, lactic acidosis, hepatotoxicity, and renal tubular damage. These profiles inform safety planning and monitoring design in experimental protocols.

Disclaimer

Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets are strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.